Table 2. Bevacizumab in low- and high-grade serous carcinoma.

Trial		No. of patients	HR
GOG-0218 [22]
	Low-grade	235	0.59
	High-grade	842	0.70
ICON7 [23]
	Grade 1	97	0.76
	Grade 2	317	0.77
	Grade 3	1,094	0.81

GOG, Gynecologic Oncology Group; HR, hazard ratio; ICON7, International Collaboration on Ovarian Neoplasms 7.